$Humacyte (HUMA.US)$ Director Dougan Brady W sold 1 million shares of common stock on May 31, Jun 3, 4, 2024 at an average price of $7.82 for a total value of $7.83 million, and purchased 2,362 shares of common stock on Jun 4, 2024 at an average price of $6.35 for a total value of $14,998.7.
This transaction involves other related parties: Niklason Laura E.
What is statement of changes in beneficial ownership of securities?
It is a requirement under federal securities laws that mandates individuals, including officers, directors, and those who hold more than 10% of any class of a company's securities (collectively known as "insiders"), to report their purchases, sales, and holdings of their company's securities by submitting Forms 3, 4, and 5.